I-Mab to Present Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Conference

I-Mab announced that it will present updated Phase 1 data on givastomig, a bispecific antibody targeting CLDN18.2 and 4-1BB, at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. The data, based on a study of 45 heavily pre-treated gastroesophageal carcinoma (GEC) patients, showed an 18% objective response rate (ORR) across various dose levels. The responses were observed regardless of CLDN18.2 expression levels, and the treatment demonstrated favorable safety. I-Mab plans to report topline Phase 1b dose expansion combination data in Q1 2026 and initiate a global randomized Phase 2 study. The presentation will take place on October 23, 2025, in Boston, Massachusetts.